A Phase 1 interventional study of GSK626616, placebo, midazolam and omeprazole, caffeine, flurbiprofen, rosiglitazone in Healthy Subjects and Anaemia, sponsored by GlaxoSmithKline. Completed at 3 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-03-19.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Anemia by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Anemia · GlaxoSmithKline.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 16th largest by enrollment, is the only one that started in 2006, is one of 14 in phase 1, and was the 1st registered.
1,810 studies on the registry are indexed under Anemia; 214 are open to participants now.
Browse Anemia studies →None of the 35 studies in Anemia by GlaxoSmithKline is open now. The open studies under Anemia, anywhere →
Of the 121 Anemia studies recruiting now, 67 (55%) set no upper age limit and 36 (30%) stop at 75 or younger; 33 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 35 interventional studies. Of the 35 that completed or were terminated, 25 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Anemia by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects. An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Omeprazole · Caffeine · Flurbiprofen · Rosiglitazone
Also known as: omeprazole, caffeine, flurbiprofen, rosiglitazone, GSK626616, placebo, midazolam
adverse events at end of each cohort
Time frame: end of each cohort
hematology/chemistry/urinalysis at end of each cohort
Time frame: end of each cohort
physical examination at end of each cohort
Time frame: end of each cohort
vital signs and electrocardiogram (ECG) at end of each cohort
Time frame: end of each cohort
GSK626616 pharmacokinetics at end of each cohort
Time frame: end of each cohort
hemoglobin at end of each cohort
Time frame: end of each cohort
red blood cell measurements at end of each cohort
Time frame: end of each cohort
estimates of CYP enzyme activity at end of study
Time frame: end of study
mRNA levels in peripheral blood at end of study
Time frame: end of study
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Omeprazole · Caffeine · Flurbiprofen · Rosiglitazone